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Abstract
The hepatic elimination of many oligopeptides is both rapid and extensive, and often limits their potential as therapeutic
 .agents. The linear, hydrophobic pseudo-hexapeptide ditekiren, a renin inhibitor, is one such example. The mechanism s
involved in its hepatic clearance are largely unknown; accordingly, the characteristics of ditekiren’s transport into isolated
rat hepatocytes was investigated. In addition to a concentration-independent, linear process, uptake also involved a
  .y1 y1.carrier-mediated component K s0.2"0.05 mM; V s11.6"0.6 pmol mg protein min . Phenobarbital pretreat-m max
ment in vivo resulted in marked induction of such transport. Negative results from cis-inhibition studies with substrates
andror inhibitors of well-established hepatic transport systems, e.g., sodium-dependent bile acid, sodium-independent
multispecific bile acid and cation carriers, ruled out their involvement in ditekiren’s uptake. By contrast, a number of cyclic
and linear oligopeptides inhibited the uptake process to varying extents and in the case of EMD-59121, the most inhibitory
compound, the interaction was competitive in nature. Collectively, these data suggest the presence of a novel high affinity,
low capacity transporter in rat hepatocytes with specific affinity for ditekiren and possibly other oligopeptides. q 1997
Elsevier Science B.V.
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1. Introduction
The therapeutic potential of biologically active
 .oligopeptides 4–10 amino acids is often limited by
Abbreviations: CCK-8, cholecystokinin octapeptide; DIDS,
4,4-diisothiocyanatostilbene-2,2X-disulfonic acid; FCCP, carbonyl
cyanide p-trifluoromethoxyphenylhydrazone; Ntcp, sodium-
taurocholate cotransporting polypeptide; Oatp1, organic anion
transporting polypeptide
)  .Corresponding author. Fax: q1 615 343-6334. E-mail:
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problems associated with drug delivery, especially
after oral administration. But, even if absorption dif-
ficulties by this route can be overcome, there remains
the further possibility of a substantial first-pass effect
by the liver and subsequent rapid hepatic elimination
from the systemic circulation. Previous studies with,
for example, an orally active renin inhibitor, ditekiren,
exemplify these problems. Even though this linear
pseudo-hexapeptide is metabolically stable, its hep-
w xatic first-pass elimination in the rat is about 70% 1
w xand removal from the body is extremely rapid 2,3
because of efficient and extensive biliary excretion
0005-2736r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0005-2736 97 00071-0
( )R.B. Kim et al.rBiochimica et Biophysica Acta 1328 1997 41–4742
w x1,3 . Such elimination involves an initial hepato-
cellular uptake process followed by secretion across
the canalicular membrane, both of which have char-
acteristics consistent with carrier-mediated transport
w x1 . An ATP-dependent, P-glycoprotein-type trans-
porter appears to be responsible for translocating
w xintracellular ditekiren into the bile canaliculus 4 ,
however, the nature and characteristics involved in
the hepatic uptake process for this and oligopeptides,
in general, are largely unknown.
A number of distinct carrier-mediated systems at
 .the hepatic basolateral sinusoidal membrane are
involved in the uptake of various endogenous and
exogenous compounds. These have mainly been de-
fined by their functional characteristics in hepato-
w xcytes 5,6 but, more recently, individual transporter
proteins have been cloned and heterologously ex-
w xpressed 7,8 . Two different mechanisms have been
described for the uptake of organic anions, i.e., Naq-
independent and Naq-dependent systems. The latter
is driven by a Naq,Kq-ATPase derived sodium gradi-
ent, and a recently cloned transporter, Ntcp, exhibits
many of the properties of this system, including the
high affinity transport of conjugated bile acids such
w xas taurocholate 8 . By contrast, non-conjugated bile
 .acids e.g., cholate and other organic anions like
bilirubin, bromosulfophthalein and a number of drugs,
e.g., pravastatin, are substrates for one or more Naq-
independent uptake systems. The cloned organic an-
 .ion transporting polypeptide Oatp1 appears to be
one protein involved in such uptake but other trans-
porters probably exist in order to account for previ-
ously observed functional characteristics, e.g., the
w xmultispecific bile acid carrier system 5,6 . Similarly,
multiple mechanisms appear to be present for the
w xhepatic uptake of organic cations 7 .
Several studies have investigated the role of these
functionally characterized transporter systems in the
hepatocellular uptake of oligopeptides. Findings with
w xboth hydrophobic cyclic and linear peptides 9–14
have, in general, indicated the involvement of a
q  . qNa -independent process es . However, a Na -de-
pendent component has been observed for other cyclic
w xoligopeptides including octreotide 15,16 and a
cationic transporter has been demonstrated to be in-
volved in the uptake of certain hydrophilic oligopep-
w xtides 17 . The present study was, therefore, under-
taken to obtain further information on the character-
istics of hepatic uptake of oligopeptides using
ditekiren as a model probe.
2. Materials and methods
2.1. Materials
w 3 xUnlabeled and radiolabeled prolyl- H ditekiren
 w xBoc-Pro-Phe-N-MeHis-Leuc CHOHCH -Val-Ile-2
 .. aminomethylpyridine , U-77436 Tham-Pro-Phe-
w x N-MeHis-Leuc CHOHCH -Val-Ile- aminomethyl-2
. pyridine-N-oxide and U-71013 Boc-Pro-Phe-N-
w x  ..MeHis-Leuc CHOHCH -Ile- aminomethylpyridine2
were obtained from The Upjohn Co. Kalamazoo,
.MI, USA . The radiopurity of the labeled peptide was
greater than 98% by thin-layer chromatography and
its specific activity was 33 mCirmmol. The renin
 inhibitors EMD-51921 Boc-Phe-Gly- amino-5-
. cyclohexyl-3-hydroxypentanoyl -Ile- N-4-amino-2-
. methyl-5-pyrimidinylmethylamide , EMD-55068 6-
aminohexanonyl-Phe-Gly- 4-amino-5-cyclohexyl-3-
. hydroxypentanoyl -Ile- N-2-amino-5,6-dimethyl-3-
.pyrazinylmethylamide were supplied by E. Merck
 . Darmstadt, Germany whereas angiopeptin lantreo-
.tide ,
a somatostatin analog, was provided by the Henri
 .Beaufour Institute Washington, DC, USA . Pro-
cainamide ethobromide was obtained from Bristol-
 .Meyers Squibb Princeton, NJ, USA and collagenase
D was purchased from Boehringer Mannheim Indi-
.anapolis, IN, USA . All other chemicals were of
reagent grade and obtained from either Fisher Scien-
 .tific Pittsburgh, PA, USA or Sigma Chemical Co.
 .St. Louis, MO, USA .
2.2. Hepatocyte preparation
Hepatocytes were prepared from 225–275 g male
 .Wistar rats Harlan Industries, Indianapolis, IN, USA
who were fed ad libitum and had free access to
drinking water. In a number of studies, rats were
pretreated for 5 days with phenobarbital 1 mgrml in
.drinking water . A total cell suspension was prepared
w xusing a modified collagenase perfusion method 18
 6and, after isolation, the cells were suspended 2=10
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. cellsrml in Tyrode buffer 137 mM NaCl, 2.7 mM
KCl, 1.8 mM CaCl , 12 mM NaHCO 5.5 mM2 3
.glucose, 0.42 mM NaH PO4, pH 7.4 at 378C into2
which 95% O –5% CO was continuously bubbled.2 2
Cell viability was determined by trypan blue exclu-
sion; generally, cell damage was less than 5% and
preparations were not used if this value exceeded
15%.
2.3. Uptake studies
Transport studies were performed in a total volume
of 2 ml consisting of 1.45 ml hepatocyte suspension,
0.5 ml Tyrode buffer solution containing unlabelled
w3 x ditekiren, and 50 ml H ditekiren in ethanol final
.concentration 0.24 mM andror various amounts of
putative inhibitors of uptake. Uptake was terminated
by rapidly transferring 0.2 ml of the incubation mix-
ture into 5 ml ice-cold, stop-solution 30 mM ditekiren
.and 200 mM phloretin in Tyrode buffer . This step
was immediately followed by rapid filtration through
pre-wetted, glass fiber filters Whatman 1.2 mm di-
.ameter, Fisher Scientific and a subsequent wash with
5 ml ice-cold, stop-solution. Filters were dissolved in
5 ml of liquid scintillation fluid BCS, Amersham,
.Arlington Heights, IL, USA and the radioactivity
determined by liquid scintillation spectrometry
 wModel 1219, Rackbeta , LKB Instruments Inc.,
.Gaithersburg, MD, USA . The measured uptake was
corrected for non-specific binding to the filter by
subtracting the amount of radioactivity present in an
w3 xaliquot taken immediately after addition of H di-
tekiren. The rate of initial uptake was estimated by
linear regression of data obtained at 10, 20, 30, 45
and 60 s after addition of labeled ditekiren. All
studies were routinely performed in duplicatertri-
plicate and were confirmed in at least three separate
hepatocyte preparations.
To define a saturable uptake process with respect
to ditekiren concentration, the initial rates of uptake
measured during incubation at 48C were subtracted
from similar values obtained following incubation at
378C. The resulting curve was subsequently analyzed
 .Fig. Perfect, Biosoft, Miltown, NJ according to
simple Michaelis-Menten type, non-linear kinetics.
An unpaired Student’s t-test was used for statistical
comparisons and P-0.05 was taken as the mini-
mum level of statistical significance.
3. Results
[ 3 ]3.1. Uptake kinetics of H ditekiren and
determinants
w 3xH Ditekiren uptake into hepatocytes was rapid
with equilibrium being reached by about 20 min; for
the first 90 s, uptake was linear over the concentra-
tion range studied, thus, allowing determination of an
 .initial uptake rate over the first 60 s Fig. 1A . The
relationship between this rate and ditekiren concen-
tration was curvilinear when determined at 378C but
 .linear at 48C Fig. 1B . The latter was interpreted to
reflect passive diffusion andror non-specific binding
and subtraction of this component revealed a sat-
urable transport process characterized by Michaelis-
Menten kinetics, with a K value of 0.20"0.05m
mM and a V value of 11.6"0.6 pmol mg pro-max
.y1 y1tein min .
The dependency of ditekiren uptake on cellular
metabolic status was assessed by replacing oxygen
with nitrogen in the gas mixture bubbled through the
hepatocyte suspension. Such pretreatment for 30 min
resulted in a 41"7% reduction in ditekiren’s initial
uptake rate which was fully reversed by subsequent
oxygenation for 30 min. In addition, pre-incubation
for 30 min with a number of known metabolic in-
hibitors or ATP-depleting agents also resulted in a
reduction in uptake: 10 mM iodoacetamide 23"
.  . 5% , 10 mM FCCP 21"8% , 1 mM ouabain 37"
.  .9 , 1 mM dinitrophenol 48"8 , 10 mM sodium
 .  .azide 44"15% , and 30 mM rotenone 63"2% .
By contrast, replacement of Naq by Kq, Liq, or
choline in the buffer solution in which the hepato-
cytes were suspended did not alter ditekiren’s uptake.
Similarly, Cly replacement with either NOy, SO2y3 4
or gluconate was without effect. Valinomycin 90
.nM , which induces an inwardly directed negative
w xpotential 14 , also did not affect ditekiren uptake,
when added to the buffer 10 min prior to addition of
labeled ditekiren. However, the electroneutral
q q  .Na rH exchanger, monensin 144 nM , resulted in
a 58"10% reduction.
[3 ]3.2. Effect of inhibitors on H ditekiren uptake
cis-Inhibition studies were performed by the addi-
tion of putative inhibitors to the hepatocyte suspen-
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w3 x  .  .Fig. 1. Time course of H ditekiren 0.24 mM uptake into rat hepatocytes Panel A and the effect of ditekiren concentration on its
 .  .  .  .initial uptake rate Panel B . Mean data"S.E. of total uptake at 378C v and 48C ’ and carrier-mediated uptaken ‘ .
w3 xsion 30 s prior to the addition of H ditekiren. No
statistically significant change in the initial uptake
rate of ditekiren was observed with taurocholate 100
.  .  .mM , cholate 100 mM , DIDS 1 mM , pro-
 .cainamide ethobromide 100 mM , N-methylnico-
 .  .  .tinamide 100 mM , and oleate 30 mM Table 1 .
 .On the other hand, bromosulfophthalein 100 mM
 .caused a 57"6% P-0.05 reduction in uptake,
Table 1
Inhibition of ditekiren transport by various compounds
Inhibitor Percentage reduction
in uptake
 .Taurocholate 100 mM 2"5
 .Cholate 100 mM 3"5
 .DIDS 1 mM 10"7
a .BSP 100 mM 57"6
 .Procainamide ethobromide 100 mM 12"9
 .N-Methylnicotinamide 100 mM 0"4
 .Oleate 30 mM 8"8
a .Phalloidin 100 mM 31"4
a .Angiopeptin 100 mM 82"1
 .CCK-8 10 mM 0"6
a .U-77436 100 mM 45"7
a .U-71013 100 mM 76"5
a .EMD-55068 100 mM 80"1
a .EMD-51921 100 mM 93"1
a P -0.05
and inhibition ranging from 0 to over 90% was also
noted with a number of cyclic and linear oligopep-
tides with varying structural similarity to ditekiren
 .Table 1, Fig. 2 . In the case of EMD-51921, such
inhibition was found to be competitive in nature with
 .a K value of 1.2 mM Fig. 3 ; other inhibitoryi
peptides were not investigated in this regard.
Fig. 2. cis-Inhibition of ditekiren’s initial uptake rate at 378C by
 .BSP \ and various oligopeptides: I CCK-8, e phalloidin, ‘
U77436, v U71013, ’ angiopeptin, wEMD 55068, l EMD
51921.
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Fig. 3. Dixon plot analysis of ditekiren transport inhibiton by
EMD51921.
[3 ]3.3. Induction of H ditekiren uptake by
phenobarbital
Pretreatment of rats with phenobarbital for 5 days
prior to hepatocyte preparation markedly increased
 .ditekiren’s initial uptake rate Fig. 4 . Kinetic analy-
sis showed that this was associated with marked
 .enhancement 10-fold of the parameters associated
with the saturable, carrier-mediated process K sm
 .y12.3"0.2 mM, V s101"5 pmol mg proteinmax
y1.min rather than the linear passive diffusion com-
ponent, which was similar to that determined in
untreated animals.
Fig. 4. Induction of ditekiren uptake in hepatocytes derived from
rats pretreated with phenobarbital. Mean data"S.E. of total
 .  .uptake at 378C v and 48C ’ and carrier-mediated uptake
 .‘ .
4. Discussion
A limiting factor in the development of potentially
useful therapeutic oligopeptides has been their rapid
hepatic elimination, which often involves biliary ex-
cretion. Such clearance requires vectorial transport
from the blood into the hepatocyte and subsequent
translocation into the bile canaliculus. Accordingly,
uptake of such oligopeptides across the basolateral
 .sinusoidal membrane into the hepatocyte is the
critical first step. The results of this study demon-
strate that two different mechanisms are involved in
this initial process with respect to the pseudo-hexa-
peptide ditekiren. First, a linear, concentration-inde-
pendent process was present consistent with passive
diffusion of this very hydrophobic oligopeptide – the
logarithm of its octanolrwater partition coefficient is
w xgreater than 4 19 . In addition, a saturable, concen-
tration-dependent uptake process exhibiting several
further characteristics of a carrier-mediated process
was definable. For example, uptake was
temperature-dependent as well as being determined
by the metabolic status of the cell, moreover, trans-
port was inhibited by several other oligopeptides but
not by non-peptide organic anions and cations, with
the exception of bromosulfophthalein. Kinetic analy-
sis indicated that this transport system had a low
capacity but a surprisingly high affinity for ditekiren
as indicated by a K value of 0.2 mM, which ism
considerably smaller than the typical K values ofm
substrates for other characterized hepatic basolateral
w xmembrane transporters 5,6 . In addition, the carrier-
mediated process was markedly induced by pretreat-
ment with phenobarbital; however, the 10-fold in-
crease in K suggests that such induction involvedm
the expression of other transporters with different
kinetic characteristics to the constitutive protein. Such
inductive effects to phenobarbital have been observed
with respect to the uptake of certain organic anions
w x20,21 ; for example, a 6-fold induction in BSP up-
take which also involved changes in both V andmax
w xK 21 .m
Recently, there has been increased interest in the
carrier-mediated transport of both endogenous and
w xexogenous compounds in the liver 5,6 , primarily as
a result of the successful cloning of a number of
individual transporters at both the basolateral and
w xcanalicular membranes 7,8 . The question, therefore,
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arises as to whether any of these well-characterized
processes are involved in the uptake of oligopeptides.
For example, the cyclic octapeptide and somatostatin
analog octreotide appears to be transported into rat
hepatocytes by an Naq-dependent process suggesting
that a bile acid transporter such as Ntcp may be
w xinvolved 15 . By contrast, the hepatocellular uptake
of several other, and structurally divergent oligopep-
tides appears to be Naq-independent; for example,
several hydrophobic cyclic oligopeptides such as the
w x w xamatoxins, like phalloidin 9 and antamanide 10 ,
w xcyclosomatostatins 11,12 , and linear renin inhibiting
w xpeptides, exemplified by EMD-51921 13,14 . Be-
cause of the broad substrate specificity of the in-
volved process, it has generally been referred to as
w xthe multispecific bile acid system 5 to distinguish it
from Naq-dependent bile acid transport. Currently, it
is not clear whether this functionally defined system
corresponds to the recently cloned Oatp1 transporter
w x7,8 and the ability of the Oatp1 to transport
oligopeptides has not been demonstrated. On the
other hand, the hepatocellular uptake of a hydropho-
 .bic, linear renin inhibitor EMD-56133 appears to
involve a Naq-independent transport system for biva-
lent cations or uncharged compounds like ouabain
w x15 . Also, several different transporters may be in-
w xvolved in the uptake of some oligopeptides 17 . Such
differences in carrier-mediated transport are not sur-
prising given the diversity of oligopeptides with re-
spect to such putative determinants as size, structure,
lipophilicity and charge. The findings with ditekiren
suggest, however, the presence of an additional and
previously undescribed transporter process for
oligopeptides.
The fact that ditekiren’s uptake was Naq-indepen-
dent and also that taurocholate did not inhibit such
transport indicate a lack of involvement of Ntcp.
Moreover, the inability of ditekiren to inhibit tauro-
cholate transport by human NTCP as well as not
being a substrate has recently been directly demon-
w xstrated 22 . Inhibition of uptake by bromosulfoph-
thalein and also monensin would be consistent with a
w xrole for the multispecific bile acid transporter 5 ,
however, several other observations do not support
this interpretation. For example, the hepatocellular
uptake of many substrates for this transporter is
Cly-sensitive and modulated by NOy, SO2y; addi-3 4
tionally, both cholate and DIDS are effective in-
w xhibitors 5 . None of these characteristics were exhib-
ited by the ditekiren carrier-mediated process; more-
over, the oligopeptide does not appear to be a sub-
strate for Oatp1 in a recombinant expression system
 .Kim, R.B. and Wilkinson, G.R., unpublished data .
w xA role for cationic hepatic transporters 5,6 would
also appear to be precluded because of the lack of
inhibition produced by procainamide ethobromide and
N-methylnicotinamide. By contrast, a number of other
oligopeptides, but not all, reduced ditekiren’s hepato-
cellular uptake suggesting a degree of specificity in
the interaction. However, these findings do not neces-
sarily indicate that such oligopeptides are substrates
for the involved transporter. EMD-51921, for exam-
ple, was the most potent inhibitor and this occurred in
a competitive fashion; however, previous studies have
shown that this renin inhibitor is transported into
hepatocytes by the multispecific bile acid transporter
with completely different functional characteristics to
w xthat of ditekiren 13,14 .
The overall findings of this study, therefore, col-
lectively suggest the presence of a transport system
for ditekiren, likely in the basolateral membrane of
hepatocytes, with characteristics unlike those previ-
ously reported for other oligopeptides. Moreover, the
 .high affinity of this carrier system K s0.2 mMm
might indicate a physiological role for endogenous
oligopeptides. Molecular cloning of such a carrier
system will be required for further characterization
and comparison with other oligopeptide transporters.
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